Tirzepatide human studies: what the trials actually show

Last updated 2026-07-27

What are the main tirzepatide human studies?

Tirzepatide's clinical case rests on two trial programs. SURPASS covers type 2 diabetes and supported FDA approval of Mounjaro in May 2022 ^[1]. SURMOUNT covers chronic weight management and supported approval of Zepbound in November 2023 ^[2]. Together these programs enrolled well over 15,000 adults across randomized, controlled, multi-year trials, which is a genuinely large base for a drug this new. SURPASS ran five core trials (SURPASS-1 through SURPASS-5), each testing tirzepatide against a different comparator: placebo, semaglutide, insulin degludec, insulin glargine, and as an add-on to existing insulin therapy. SURMOUNT ran four core trials (SURMOUNT-1 through SURMOUNT-4) plus later add-ons like SURMOUNT-J (a Japanese population trial) and SURMOUNT-OSA (looking at sleep apnea). All of this is public. Eli Lilly, the manufacturer, registered every trial on ClinicalTrials.gov with an NCT number, and the key results were published in the New England Journal of Medicine, The Lancet, and JAMA. That's the standard you want to see before trusting any drug, and tirzepatide clears it. Compounded versions of tirzepatide, by contrast, have not been studied in their own separate trials; they rely on the same active-ingredient data because the molecule is identical, but the specific compounded formulation, concentration, or delivery device has not been through FDA trial review. If you're mapping out how the studied doses translate into a real regimen, the Tirz Rx dosage guide walks through how titration in practice mirrors what these trials used.

What did SURMOUNT-1 find for weight loss?

SURMOUNT-1 is the trial most people mean when they cite tirzepatide's weight-loss numbers. It enrolled 2,539 adults with obesity or overweight plus a weight-related condition, none of whom had diabetes, and ran for 72 weeks (NCT04184622) ^[3]. The results, published in the New England Journal of Medicine in 2022: participants on 15 mg lost a mean of 22.5% of body weight, 10 mg produced 21.4%, and 5 mg produced 16.0%, compared with 2.4% on placebo ^[3]. The trial's own conclusion states tirzepatide produced 'substantial and sustained reduction in body weight' across all three doses tested. More strikingly, 91% of people on the 15 mg dose lost at least 5% of body weight, and over half lost more than 20%. Those are trial averages under close medical supervision with regular dose titration, not a promise for any one person. Real-world results run lower on average, partly because trial participants get more support and monitoring than a typical prescription does. Still, no other approved weight-loss drug has posted numbers like this in a trial of this size.

How does tirzepatide perform for type 2 diabetes (SURPASS)?

SURPASS-2 is the trial that got the most attention here because it pitted tirzepatide directly against semaglutide 1 mg, the top GLP-1 diabetes drug at the time. Published in the New England Journal of Medicine in 2021, it enrolled 1,879 adults with type 2 diabetes (NCT03987919) ^[4]. At 40 weeks, tirzepatide 15 mg lowered A1c by 2.30 percentage points versus 1.86 points for semaglutide 1 mg, and produced more weight loss too: about 11.2 kg versus 5.7 kg ^[4]. That's a meaningful separation between two active drugs, more than a placebo comparison, and it's part of why tirzepatide gets described as a step up rather than a lateral move within the GLP-1 class. Across the SURPASS program as a whole, A1c reductions ranged from roughly 1.9 to 2.6 percentage points depending on baseline A1c and dose, with many participants reaching an A1c under 7% or even under 5.7% (the threshold generally used to define non-diabetic range) ^[1]. SURPASS-4, a larger cardiovascular-risk-focused trial with over 2,000 participants comparing tirzepatide to insulin glargine, also found tirzepatide non-inferior for major cardiovascular events, an important secondary finding for a diabetes drug given how much of that population's risk is cardiac ^[1].

What's the difference between the SURMOUNT trials?

The four core SURMOUNT trials tested tirzepatide in different populations and settings, and knowing which one applies to your situation matters more than just knowing 'tirzepatide works.' | Trial | Population | Duration | Key finding |

What side effects showed up in the human trials?

Gastrointestinal side effects are the headline finding across every tirzepatide trial, and they're dose-related. In SURMOUNT-1, nausea affected up to 31%, diarrhea up to 23%, and vomiting up to 12% of participants depending on dose, most of it during dose escalation rather than at steady state ^[3]. These mirror what's seen with other GLP-1 drugs like semaglutide, just possibly a bit more frequent given tirzepatide's added GIP activity. Discontinuation due to side effects ran higher than placebo but wasn't dramatic: about 4.3% to 7.1% of tirzepatide-treated participants in SURMOUNT-1 stopped the drug because of adverse events, versus 2.6% on placebo ^[3]. Most people who get through the first few dose increases tolerate the drug reasonably well. Beyond GI symptoms, the trials also tracked gallbladder-related events (cholelithiasis and cholecystitis showed up more often on tirzepatide than placebo across the SURMOUNT program), injection site reactions, and rare cases of acute pancreatitis. The FDA label for both Zepbound and Mounjaro carries warnings about pancreatitis risk and advises against use in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on thyroid C-cell tumors seen in rodent studies. That contraindication is a boxed warning, the FDA's most serious labeling category, not a footnote ^[8]. None of this means the drug is unusually dangerous. It means the risk profile is real, dose-dependent for GI effects, and worth taking seriously rather than dismissing. If you're new to injections generally, the practical side of managing tolerability starts with technique; see Tirz Rx how to inject and Tirz Rx injection sites for how site rotation and injection method affect local reactions.

Does tirzepatide help with sleep apnea or other conditions?

Yes, at least for obstructive sleep apnea. SURMOUNT-OSA, published in the New England Journal of Medicine in 2024, enrolled adults with obesity and moderate-to-severe obstructive sleep apnea and found tirzepatide reduced the apnea-hypopnea index (AHI, a measure of breathing interruptions per hour of sleep) by a mean of roughly 25 to 29 events per hour more than placebo, depending on whether participants used positive airway pressure therapy alongside it ^[9]. That result was strong enough that the FDA approved Zepbound specifically for moderate-to-severe OSA in adults with obesity in December 2024, the first drug approved for that indication ^[10]. Beyond OSA, tirzepatide has been studied for cardiovascular outcomes (the SURMOUNT-MMO and SURPASS-CVOT trials are ongoing or reporting), and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), with early-phase data suggesting liver fat reduction, though that indication is not yet FDA-approved. It's reasonable to expect more approved uses in the next few years as these trials mature, but right now the FDA-cleared indications remain type 2 diabetes (Mounjaro) and chronic weight management with or without OSA (Zepbound) ^[2][10].

How does tirzepatide compare to semaglutide in head-to-head trials?

The clearest head-to-head data is SURPASS-2 (diabetes) already covered above, and a separate trial called SURMOUNT vs. STEP isn't a direct comparison since those come from different sponsors and populations. But there is a real head-to-head weight-loss trial worth naming: SURMOUNT-5, which compared tirzepatide directly to semaglutide 2.4 mg (Wegovy) in adults with obesity, without diabetes. Results presented in 2024 found tirzepatide produced about 20.2% mean weight loss versus 13.7% for semaglutide over roughly 72 weeks, a difference of about 6.5 percentage points favoring tirzepatide ^[11]. That's the best direct evidence available for the 'which drug works better' question, since indirect cross-trial comparisons (comparing SURMOUNT-1 to STEP 1, for instance) are weaker science; different trial populations, different eras, different dropout patterns. Worth remembering: head-to-head superiority in a trial doesn't mean semaglutide is a bad drug, or that tirzepatide is right for everyone. Cost, side effect tolerance, insurance coverage, and injection frequency all factor into a real decision, and a table further down covers where compounded access changes that calculus.

How do the trial doses map to what patients actually take?

Every SURPASS and SURMOUNT trial used the same weekly subcutaneous injection schedule and dose-escalation logic that's now on the FDA label: start at 2.5 mg once weekly for four weeks, then increase in 2.5 mg increments every four weeks as tolerated, up to a maximum studied dose of 15 mg once weekly ^[1][2]. The 2.5 mg starting dose is a run-in dose meant to build tolerance; it's not expected to produce much weight loss or A1c change on its own. | Trial dose | Common outcome (approx.) |

Is compounded tirzepatide backed by the same trial data?

Partially, and the distinction matters. The active ingredient, tirzepatide, is the same molecule studied in SURPASS and SURMOUNT regardless of whether it comes in a Lilly-manufactured Mounjaro or Zepbound pen or a compounded vial from a state-licensed pharmacy. The biological effects on weight, A1c, and appetite reflect the same mechanism. What's not covered by those trials is the specific manufacturing process, sterility assurance, concentration accuracy, and stability of any individual compounded batch. FDA-approved drugs go through a review of the exact manufacturing site and process as part of approval; compounded versions, made under state pharmacy law and (in the case of 503A or 503B facilities) different federal oversight rules, don't get that same drug-specific trial-based review. The FDA has published warnings about compounded tirzepatide products found to contain incorrect salt forms or impurities not present in the approved drug . This is exactly why using a provider-reviewed pathway that sources from a legitimate, tested pharmacy matters if you go the compounded route. Tirz Rx works with providers who review your history before prescribing and routes fulfillment through a licensed pharmacy partner rather than an unverified vendor, which is a meaningfully different risk profile than ordering from an anonymous online seller.

What are the real limitations of the tirzepatide trial data?

Every trial has boundaries worth knowing. SURMOUNT-1 and most SURPASS trials ran 40 to 72 weeks, meaning the longest controlled safety and efficacy data available for tirzepatide is under two years; longer-term data comes from open-label extensions and post-marketing surveillance, which are useful but weaker forms of evidence than randomized controlled trials. Trial populations also skew toward people healthy enough to qualify and motivated enough to complete a multi-month protocol with regular clinic visits, which isn't identical to the general population taking the drug under normal clinical conditions. Dropout rates matter too: across SURMOUNT-1, roughly 14% to 16% of tirzepatide participants discontinued the trial for any reason by 72 weeks, which analysts account for using statistical methods, but it's still a real gap between 'randomized to drug' and 'took drug as prescribed for the full study.' Finally, most trials excluded people with a history of pancreatitis, medullary thyroid cancer or MEN 2, severe GI disease, or significant psychiatric conditions, so the safety data doesn't directly speak to those groups; that's precisely why those exclusions became contraindications and warnings on the label rather than open questions.

Frequently asked questions

How many people have been studied in tirzepatide clinical trials?

Across the SURPASS (diabetes) and SURMOUNT (weight) trial programs combined, well over 15,000 adults have been enrolled in randomized controlled trials, plus tens of thousands more in post-marketing follow-up and safety databases since FDA approval in 2022 (Mounjaro) and 2023 (Zepbound).

What was the main finding of SURMOUNT-1?

SURMOUNT-1 found that adults with obesity or overweight lost a mean of 22.5% of body weight on tirzepatide 15 mg over 72 weeks, versus 2.4% on placebo, with 91% of the 15 mg group losing at least 5% of body weight. It was published in the New England Journal of Medicine in 2022.

Did SURPASS-2 really show tirzepatide beats semaglutide?

Yes, for the doses tested. SURPASS-2 found tirzepatide 15 mg lowered A1c by 2.30 points versus 1.86 points for semaglutide 1 mg, and produced more weight loss (about 11.2 kg vs 5.7 kg) over 40 weeks in adults with type 2 diabetes.

What happens if you stop taking tirzepatide after losing weight?

SURMOUNT-4's withdrawal arm found that people who switched from tirzepatide to placebo after 36 weeks regained a substantial portion of lost weight by week 88, while those who continued the drug kept losing. This suggests tirzepatide needs ongoing use to maintain results, similar to other anti-obesity drugs.

Is tirzepatide approved for sleep apnea?

Yes. The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, based on the SURMOUNT-OSA trial, which found reductions in the apnea-hypopnea index of roughly 25 to 29 events per hour versus placebo.

What are the most common tirzepatide side effects in trials?

Nausea, diarrhea, vomiting, and constipation are the most common, affecting up to about 31% of participants (nausea) at higher doses in SURMOUNT-1. Most GI side effects happen during dose escalation and ease at a stable dose. Discontinuation for side effects occurred in roughly 4% to 7% of tirzepatide-treated participants.

Does tirzepatide carry a thyroid cancer warning?

Yes. Both Mounjaro and Zepbound carry an FDA boxed warning about thyroid C-cell tumors seen in rodent studies, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is the FDA's most serious warning category.

Is compounded tirzepatide backed by the same clinical trials as Zepbound or Mounjaro?

The active ingredient is the same molecule studied in the trials, but the specific compounded formulation, concentration, and manufacturing process haven't been through FDA drug-specific review the way branded Mounjaro and Zepbound have. The FDA has flagged some compounded tirzepatide products for impurities or incorrect salt forms.

How long do the tirzepatide trials run, and is there long-term data?

Most core SURPASS and SURMOUNT trials ran 40 to 88 weeks. Longer-term safety data comes from open-label extensions and post-marketing surveillance rather than new randomized trials, so data beyond about two years is weaker evidence than the core trial results.

Does tirzepatide work as well for people who already have type 2 diabetes as for people who don't?

Generally, people with type 2 diabetes lose somewhat less weight on tirzepatide than people without diabetes. SURMOUNT-2 (diabetes population) found about 15.7% mean weight loss at 15 mg, compared to 22.5% in the non-diabetic SURMOUNT-1 population, likely due to insulin resistance.

What is the difference between SURPASS and SURMOUNT trials?

SURPASS trials studied tirzepatide (as Mounjaro) for type 2 diabetes, measuring A1c reduction as the primary outcome. SURMOUNT trials studied tirzepatide (as Zepbound) for chronic weight management in people with obesity or overweight, measuring percent body weight loss as the primary outcome.

Has tirzepatide been compared directly to semaglutide for weight loss, more than diabetes?

Yes, SURMOUNT-5 compared tirzepatide directly to semaglutide 2.4 mg in adults with obesity without diabetes and found about 20.2% mean weight loss on tirzepatide versus 13.7% on semaglutide over roughly 72 weeks, a direct head-to-head result rather than a cross-trial comparison.

Sources

1. FDA, Mounjaro (tirzepatide) approval and prescribing information: Mounjaro FDA approval, SURPASS trial program dosing and titration schedule, cardiovascular non-inferiority findings
2. FDA, Zepbound (tirzepatide) approval announcement: Zepbound FDA approval for chronic weight management, November 2023
3. Jastreboff AM, et al., New England Journal of Medicine, 'Tirzepatide Once Weekly for the Treatment of Obesity' (SURMOUNT-1): SURMOUNT-1 weight loss results, side effect rates, discontinuation rates, trial design (NCT04184622)
4. Frias JP, et al., New England Journal of Medicine, 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes' (SURPASS-2): SURPASS-2 head-to-head A1c and weight loss results versus semaglutide 1 mg (NCT03987919)
5. Le Roux CW, et al., The Lancet, 'Tirzepatide for the treatment of obesity in people with type 2 diabetes' (SURMOUNT-2): SURMOUNT-2 weight loss results in participants with type 2 diabetes
6. Wadden TA, et al., JAMA, 'Tirzepatide after Intensive Lifestyle Intervention' (SURMOUNT-3): SURMOUNT-3 additional weight loss after lifestyle intervention lead-in
7. Aronne LJ, et al., JAMA, 'Continued Treatment with Tirzepatide for Maintenance of Weight Reduction' (SURMOUNT-4): SURMOUNT-4 withdrawal design showing weight regain after stopping tirzepatide
8. FDA, Zepbound prescribing information (boxed warning): Boxed warning on thyroid C-cell tumor risk and MEN 2 contraindication
9. Malhotra A, et al., New England Journal of Medicine, 'Tirzepatide for the Treatment of Obstructive Sleep Apnea' (SURMOUNT-OSA): SURMOUNT-OSA apnea-hypopnea index reduction results
10. FDA, press announcement on Zepbound approval for obstructive sleep apnea: FDA approval of Zepbound for moderate-to-severe OSA, December 2024, first drug approved for that indication
11. FDA, 'Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss' compounding warnings page: FDA warnings regarding compounded GLP-1/GIP product quality and impurity concerns